

NHS New Medicines Decisions for February 2024

anemerani	(Kapruvia®)			
SMC Drug ID	Conditions	Decision	Date of ADTC	Date of decision / Expected date of decision
SMC2623	treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult patients on haemodialysis.	Not routinely available as there is a local preference for alternative medicines	28/02/2024	28/02/2024
	SMC restriction: for use in patients with an inadequate response to best supportive care for reducing itch.			
Other Decision	n Specified :			
Other Decisio				
	•	pruvia-final-ian-2024-for-website.pdf		
	ttps://www.scottishmedicines.org.uk/media/8108/difelikefalin-kap	pruvia-final-jan-2024-for-website.pdf		
Web Link: ht	ttps://www.scottishmedicines.org.uk/media/8108/difelikefalin-kap	oruvia-final-jan-2024-for-website.pdf		
Web Link: ht	•	pruvia-final-jan-2024-for-website.pdf Decision	Date of ADTC	Date of decision / Expected date of decision
Web Link: ht	ttps://www.scottishmedicines.org.uk/media/8108/difelikefalin-kap		Date of ADTC 28/02/2024	
Web Link: ht	ttps://www.scottishmedicines.org.uk/media/8108/difelikefalin-kap b (Ultomiris®) Conditions As an add-on to standard therapy for the treatment of adult patients with generalized myasthenia gravis (gMG) who are	Decision Not routinely available as not recommended for use in		/ Expected date of decision

Page 1 of 4 03 July 2024 15:03:47



NHS New Medicines Decisions for February 2024

SMC Drug ID	Conditions	Decision	Data of ADTC	Data of docision
SMC Drug ID	Conditions	Decision	Date of ADTC	Date of decision / Expected date of decision
SMC2590	as monotherapy for the treatment of adult patients with locally advanced or metastatic differentiated thyroid carcinoma (DTC), refractory or not eligible to radioactive iodine (RAI) who have progressed during or after prior systemic therapy.	NILIO O carla cal	28/02/2024	28/02/2024
Other Decisio	n Specified :			
MAZARA I SANTA A TAN		hamatus final inc 0004 for such site walf		
Web Link: ht	ttps://www.scottishmedicines.org.uk/media/8107/cabozantinib-ca	bometyx-final-jan-2024-for-website.pdf		
Web Link: ht	ttps://www.scottishmedicines.org.uk/media/8107/cabozantinib-ca	bometyx-final-jan-2024-for-website.pdf		
	·	bometyx-final-jan-2024-for-website.pdf		
	ttps://www.scottishmedicines.org.uk/media/8107/cabozantinib-ca	bometyx-final-jan-2024-for-website.pdf		
	·	bometyx-final-jan-2024-for-website.pdf Decision	Date of ADTC	Date of decision / Expected date of decision
secukinuma	ab (Cosentyx®)		Date of ADTC 28/02/2024	/ Expected date
secukinuma SMC Drug ID	for the treatment of active moderate to severe hidradenitis suppurativa (HS) (acne inversa) in adults with an inadequate response to conventional systemic HS therapy.	Decision	30.00 0.7.3	/ Expected date of decision

Page 2 of 4 03 July 2024 15:03:47



dupilumab (Dupixent®)

NHS New Medicines Decisions for February 2024

SMC Drug ID	Conditions	Decision	Date of ADTC	Date of decision / Expected date of decision
SMC2598	for the treatment of adults with moderate-to-severe prurigo nodularis (PN) who are candidates for systemic therapy.	Available in line with local or regional guidance	28/02/2024	28/02/2024
Other Decisio	n Specified :			
Web Link: ht	tps://www.scottishmedicines.org.uk/media/8109/dupilumab-dupi:	xent-final-jan-2024-for-website.pdf		
			·	·
Ioncastuxin	nab tesirine (Zynlonta®)			
SMC Drug ID	Conditions	Decision	Date of ADTC	Date of decision / Expected date of decision
SMC2609	as monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy.	Available in line with local or regional guidance	28/02/2024	28/02/2024
	SMC restriction: where chimeric antigen receptor (CAR) T-cell therapy is unsuitable, not tolerated or ineffective.			
Other Decisio	n Specified :			
Web Link: ht	tps://www.scottishmedicines.org.uk/media/8110/loncastuximab-t	esirine-zvnlonta-final-ian-2024-for-website.pdf		
WED LINK. III	tps://www.scottisnmedicines.org.divinedia/o i ro/ioncastaximab-t	esime-zymonta-imar-jan-zoz-r-tor-website.pur		

Page 3 of 4 03 July 2024 15:03:47



NHS New Medicines Decisions for February 2024

SMC Drug ID	Conditions	Decision	Date of ADTC	Date of decision / Expected date of decision
SMC2658	Treatment of adult patients with neuromyelitis optica spectrum disorder (NMOSD) who are anti-aquaporin 4 (AQP4) antibodypositive.	Not routinely available as not recommended for use in NHS Scotland	28/02/2024	28/02/2024
Other Decision	n Specified: Non-submission			
Web Link: ht	tps://www.scottishmedicines.org.uk/media/8105/ravulizumab-ulto	miris-nmosd-non-sub-final-jan-2024-for-website.pdf		

Page 4 of 4 03 July 2024 15:03:47